If you have been reading about triple agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-25. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
To test this therapeutic hypothesis, a selective and blood-brain barrier-permeable OGA inhibitor, thiamet-G, was developed. Thiamet-G treatment was able to increase tau O-GlcNAcylation and suppress tau phosphorylation in cell culture and in vivo in healthy Sprague-Dawley rats. A subsequent study showed that thiamet-G treatment also increased tau O-GlcNAcylation in a JNPL3 tau transgenic mouse model. In this model, tau phosphorylation was not significantly affected by thiamet-G treatment, though decreased numbers of neurofibrillary tangles and slower motor neuron loss were observed. Additionally, O-GlcNAcylation of tau was noted to slow tau aggregation in vitro. OGA inhibition with MK-8719 is being investigated in clinical trials as a potential treatment strategy for Alzheimer's disease and other tauopathies including progressive supranuclear palsy.
To maintain a high constant body temperature is energy expensive—mammals therefore need a nutritious and plentiful diet. While the earliest mammals were probably predators, different species have since adapted to meet their dietary requirements in a variety of ways. Some eat other animals—this is a carnivorous diet (and includes insectivorous diets). Other mammals, called herbivores, eat plants, which contain complex carbohydrates such as cellulose. An herbivorous diet includes subtypes such as granivory (seed eating), folivory (leaf eating), frugivory (fruit eating), nectarivory (nectar eating), gummivory (gum eating) and mycophagy (fungus eating). The digestive tract of an herbivore is host to bacteria that ferment these complex substances, and make them available for digestion, which are either housed in the multichambered stomach or in a large cecum. Some mammals are coprophagous, consuming feces to absorb the nutrients not digested when the food was first ingested. An omnivore eats both prey and plants. Carnivorous mammals have a simple digestive tract because the proteins, lipids and minerals found in meat require little in the way of specialized digestion. Exceptions to this include baleen whales who also house gut flora in a multi-chambered stomach, like terrestrial herbivores. The size of an animal is also a factor in determining diet type (Allen's rule). Since small mammals have a high ratio of heat-losing surface area to heat-generating volume, they tend to have high energy requirements and a high metabolic rate.
Fredric Sheldon Brandt (June 26, 1949 – April 5, 2015) was an American physician, researcher, lecturer, author, and radio host specializing in cosmetic dermatology. Among the first to use botulinum toxin ("botox") and fillers, Brandt was noted for his role in the FDA approval of numerous fillers and botulinum toxins for cosmetic use in the United States. Brandt, who hosted a radio show called Ask Dr. Brandt on SiriusXM radio and whose celebrity patients included Madonna, was called the "Baron of Botox" by W magazine and "King of Collagen" for using more botox and collagen than any other dermatologist in the world.
Sources: en.wikipedia.org
== Health == Type V Collagen studies show that Collagen V plays some other roles in different parts of the body. These roles can be both beneficial and harmful. Beneficial roles that Type V collagen plays in the body are:
Rheumatoid arthritis - autoimmune disease with an unclear cause that manifests as symmetric, erosive synovitis and, occasionally, extraarticular involvement. Systemic lupus erythematosus - chronic, complex autoimmune inflammatory disorder that can affect every organ in the body. Scleroderma and systemic scleroderma - diverse collection of autoimmune fibrosing conditions. Dermatomyositis and polymyositis - autoimmune myopathies that are clinically characterized by extramuscular symptoms, muscle inflammation, proximal muscle weakening, and oftentimes the detection of autoantibodies. Antisynthetase syndrome - multisystematic autoimmune disease associated with inflammatory myositis and interstitial lung disease. Vasculitis - disease that results in blood vessel inflammation. Sjögren's disease - a systemic autoimmune illness that mostly affects the exocrine glands and causes mucosal surfaces, especially those in the mouth and eyes, to become extremely dry. Rheumatic fever - multisystem inflammatory illness that develops after group A streptococcal pharyngitis. Amyloidosis - uncommon condition caused by protein mutations or changes in the body that result in twisted clusters of malformed proteins accumulating on organs and tissues. Osteoarthritis - common articular cartilage degenerative disease linked to hypertrophic bone abnormalities.
Americium is used in the most common type of household smoke detector, which uses 241Am in the form of americium dioxide as its source of ionizing radiation. This isotope is preferred over 226Ra because it emits 5 times more alpha particles and relatively little harmful gamma radiation. The amount of americium in a typical new smoke detector is 1 microcurie (37 kBq) or 0.29 microgram. This amount declines slowly as the americium decays into neptunium-237, a different transuranic element with a much longer half-life (about 2.14 million years). With its half-life of 432.2 years, the americium in a smoke detector includes about 3% neptunium after 19 years, and about 5% after 32 years. The radiation passes through an ionization chamber, an air-filled space between two electrodes, and permits a small, constant current between the electrodes. Any smoke that enters the chamber absorbs the alpha particles, which reduces the ionization and affects this current, triggering the alarm. Compared to the alternative optical smoke detector, the ionization smoke detector is cheaper and can detect particles which are too small to produce significant light scattering; however, it is more prone to false alarms.
Sources: en.wikipedia.org
The electric bath for high-voltage static induction Oudin coil, a high-voltage induction coil, in use around 1900 Faradic battery, a device to provide localised electric stimulation Pulvermacher's chain, a wearable electrochemical device mostly used by quacks, in use during the second half of the 19th century. Leyden jars, an early form of capacitor, for storing electricity Electrostatic generators of various sorts
=== Tankmates === The croaking gourami should not be kept with large, aggressive fish, and pairs wells with other small, peaceful fish, as well as with fellow gouramis. Male bettas are known to target this species, so bettas should not be kept as tankmates.
== Sources == Broodbank, Cyprian (2013). The Making of the Middle Sea: A History of the Mediterranean from the Beginning to the Emergence of the Classical World. London: Thames & Hudson. ISBN 978-0-500-29208-2. Brown, K.; Fa, D. A.; Finlayson, G.; Finlayson, C. (2011). "Small game and marine resource exploitation by Neanderthals: the evidence from Gibraltar". Trekking the shore: changing coastlines and the antiquity of coastal settlement. Interdisciplinary contributions to archaeology. Springer. ISBN 978-1-4419-8218-6. Finlayson, C. (2019). The smart Neanderthal: bird catching, cave art, and the cognitive revolution. Oxford University Press. ISBN 978-0-19-251812-5. French, Jennifer (2021). Palaeolithic Europe: A Demographic and Social Prehistory. Cambridge University Press. ISBN 978-1-108-49206-5. Papagianni, D.; Morse, M. A. (2013). "Still with us?". Neanderthals rediscovered: how modern science is rewriting their story. Thames and Hudson. ISBN 978-0-500-77311-6. Reich, D. (2018). "Encounters with Neanderthals". Who we are and how we got here: ancient DNA and the new science of the human past. Oxford University Press. ISBN 978-0-19-882125-0. Shipman, P. (2015). "How humans and their dogs drove Neanderthals to extinction". The invaders: how humans and their dogs drove Neanderthals to extinction. Harvard University Press. doi:10.2307/j.ctvjf9zbs. ISBN 978-0-674-42538-5. JSTOR j.ctvjf9zbs. Tattersall, I. (2015). "Neanderthals, DNA, and creativity". The strange case of the Rickety Cossack: and other cautionary tales from human evolution. St. Martin's Publishing Group.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.